A landmark international clinical trial has found that radiotherapy can be safely omitted in many patients with early-stage breast cancer who have undergone mastectomy and are receiving modern chemotherapy. These findings challenge long-standing clinical protocols and suggest a potential paradigm shift in postmastectomy care aimed at minimizing unnecessary interventions while maintaining survival outcomes.
Historically, radiation therapy targeting the chest wall after mastectomy was standard practice to eradicate residual cancer cells and reduce the risk of local recurrence. These recommendations are largely informed by experiments conducted in the 1980s. However, these early studies occurred before the introduction of modern systemic therapies and advanced surgical techniques, raising questions about the continued need for chest wall radiotherapy in the current clinical setting.
The SUPREMO trial, short for Selective Use of Postoperative Radiotherapy after Mastectomy, was designed to address these uncertainties, led by researchers at the University of Edinburgh and involving collaborators from 17 countries. We enrolled 1,607 women with intermediate-risk breast cancer characterized by one to three positive lymph nodes or specific pathological features indicative of an aggressive tumor without lymph node involvement.
Participants underwent mastectomy and axillary surgery, followed by lymphadenectomy to assess lymph node involvement. All received modern systemic anticancer therapy reflecting current standards of care, including chemotherapy, hormonal therapy, and appropriate targeted agents. Patients were then randomly assigned to receive chest wall radiation therapy or no further radiation therapy, and the trial tracked outcomes over 10 years.
After 10 years of surveillance, data showed no statistically significant difference in overall survival between the radiotherapy and nonradiation treatment groups. Survival rates were nearly identical, 81.4% vs. 81.9%, respectively. Moreover, radiotherapy did not provide measurable benefits in disease-free survival or prevention of distant metastases, outcomes that are important indicators of cancer recurrence and progression.
Local recurrence of the chest wall, a traditional metric used to justify postoperative radiotherapy, was rare in both cohorts. Importantly, the trial observed only a small reduction in local recurrences in women who received radiation therapy (nine compared with 20 in the control group). Adverse effects from radiation were generally mild, and no increase in treatment-related cardiac mortality was found, allaying some concerns about potential long-term cardiac toxicity.
Researchers attribute these findings to breakthroughs in systemic treatments that have significantly reduced the likelihood of cancer recurrence beyond what can be achieved with radiation alone. These improvements in pharmacological treatment modalities effectively improve distant disease control and survival, modulating the relative benefit of adding chest wall radiotherapy.
Although the SUPREMO trial focused only on patients with an intermediate risk profile, its insights encourage careful consideration of individualized treatment plans. High-risk patients characterized by extensive lymph node involvement or other aggressive clinical features were not included in the study population and may still derive meaningful benefit from postmastectomy radiotherapy.
This study, published in the prestigious New England Journal of Medicine, leverages powerful randomized controlled trial methods to provide powerful evidence that can help reshape clinical guidelines worldwide. This highlights the need to continually reassess established treatment practices in the context of an evolving treatment environment.
Clinical experts emphasize that omitting radiotherapy can reduce the treatment burden on patients and protect them from acute and chronic toxicities associated with radiation, including skin changes, fibrosis, fatigue, and potential impairment of reconstructive surgery outcomes. Additionally, reductions in health system resource utilization are consistent with the broader goal of providing cost-effective cancer care without compromising quality.
The trial was conducted as a collaborative effort across multiple academic institutions and was supported by notable funding agencies, including the Medical Research Council and the National Institute for Health and Care Research. This international partnership exemplifies the important role of coordinated research networks in answering important clinical questions.
Key opinion leaders argue that these findings should be integrated into multidisciplinary discussions to tailor treatments to individual risk profiles and patient preferences. Avoiding unnecessary radiotherapy not only improves patients’ quality of life, but may also optimize treatment sequencing in the management of complex breast cancer.
Professor Ian Kunkler, from the University of Edinburgh, commented on the importance of the trial, saying there was no evidence to support continued routine radiotherapy for intermediate-risk mastectomy patients receiving modern systemic therapy. Complementing this, Dr Nicola Russell from the Netherlands Cancer Institute emphasized the importance of reducing unnecessary radiation to minimize side effects and preserve reconstructive options.
In summary, the SUPREMO trial highlights innovative directions for the treatment of breast cancer after mastectomy and improves treatment protocols toward precision medicine and patient-centered medicine by advocating for a nuanced approach that leverages advances in systemic treatment that could potentially lead to forgoing radiotherapy in selected patients.
Research subject: people
article title: (not provided)
web reference:
References: SUPREMO clinical trial published in New England Journal of Medicine
image credit: (not provided)
keyword: Breast cancer, radiation therapy, cancer treatment
Tags: Addressing cancer treatment paradigmsNecessity of chest wall radiotherapyClinical trials for breast cancerEarly breast cancer treatmentInternational Breast Cancer Research CollaborationNode involvement in breast cancerMinimizing cancer treatment interventionsModern anti-cancer drug therapyPost-mastectomy treatment protocolsMissing radiotherapy after mastectomySUPREMO trial resultsUnnecessary radiotherapy for breast cancer
